[Discussion] we are measuring state board at the wrong time and calling it noise
we are measuring state board at the wrong time and calling it noise. I have gone back and forth on this for months.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
I would not read the price difference as a quality signal.
Agreed — and the follow-up question is what the beyond-use date is based on.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Compounded preparations are not approved products and carry no bioequivalence claim.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Is the compound still on the shortage list where you are?
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Correction: patient-specific refers to the prescription, not to a bespoke formulation.
This is the distinction the whole board runs on. Everything else follows from it.
the API source is the question nobody asks and everybody should
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
ask which facility, then ask for their testing
- 1Compounded preparations are not approved products and carry no…11 comments in this branch · started by u/kavya_kravchenko